Mupirocin/chlorexidine to prevent methicillin-resistant Staphylococcus aureus infections: Post hoc analysis of a placebo-controlled, randomized trial using mupirocin/chlorhexidine and polymyxin/tobramycin for the prevention of acquired infections in intubated patients

Infection

Volumn 42, Issue 3, 2014, Pages 493-502

  Camus, C ^a,b   Sebille, V ^c   Legras, A ^d   Garo, B ^e   Renault, A ^e   Le Corre, P ^a   Donnio, P Y ^a   Gacouin, A ^a,b   Perrotin, D ^d   Le Tulzo, Y ^a,b   Bellissant, E ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Universite de Nantes   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Chlorhexidine; ICU acquired infection; MRSA; Mupirocin; Selective digestive decontamination; Staphylococcus aureus

Indexed keywords

CHLORHEXIDINE; CHLORHEXIDINE GLUCONATE; COLISTIN; PLACEBO; PSEUDOMONIC ACID; TOBRAMYCIN; ANTIINFECTIVE AGENT; POLYMYXIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FACTORIAL DESIGN; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; INTUBATION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; TOPICAL TREATMENT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; FRANCE; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHLORHEXIDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INTUBATION; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MUPIROCIN; PLACEBOS; POLYMYXINS; STAPHYLOCOCCAL INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901677658     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0581-1     Document Type: Article

References (42)

1. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006;368:874-85. (Pubitemid 44308640)
2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14.
3. Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus? Clin Infect Dis. 2010;51:585-90.
4. Warren DK, Guth RM, Coopersmith CM, Merz LR, Zack JE, Fraser VJ. Epidemiology of methicillin-resistant Staphylococcus aureus colonization in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2006;27:1032-40. (Pubitemid 44670978)
5. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368:533-42.
6. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;68:2255-65.
7. Huskins WC, Huckabee CM, O'Grady NP, Murray P, Kopetskie H, Zimmer L, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med. 2011;364:1407-18.
8. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39:776-82. (Pubitemid 39244289)
9. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med. 2008;121:310-5. (Pubitemid 351417832)
10. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke- Grauls CM, Roosendaal R, et al. Preventing surgicalsite infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362:9-17.
11. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care.Cochrane Database Syst Rev. 2009; (4):CD000022. doi: 10.1002/14651858.CD000022.pub
12. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet. 2003;362:1011-6. (Pubitemid 37186877)
13. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009;360:20-31.
14. Camus C, Bellissant E, Sebille V, Perrotin D, Garo B, Legras A, et al. Prevention of acquired infections in intubated patients with the combination of two decontamination regimens. Crit Care Med. 2005;33:307-14. (Pubitemid 40216542)
15. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-40.
16. Courvalin P. Interpretive reading of in vitro antibiotic susceptibility tests (the antibiogramme). Clin Microbiol Infect. 1996;2:S26-34. (Pubitemid 126682698)
17. Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother. 1997;41:1137-9. (Pubitemid 27194199)
18. Hall DB. Zero-inflated Poisson and binomial regression with random effects: a case study. Biometrics. 2000;56:1030-9.
19. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289:2545-53. (Pubitemid 37430156)
20. Jarlier V, Trystram D, Brun-Buisson C, Fournier S, Carbonne A, Marty L, et al. Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med. 2010;170:552-9.
21. Edgeworth JD. Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care. J Antimicrob Chemother. 2011;66:ii41-7.
22. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66:iv43-8.
23. Lepelletier D, Richet H. Surveillance and control of methicillinresistant Staphylococcus aureus infections in French hospitals. Infect Control Hosp Epidemiol. 2001;22:677-82. (Pubitemid 34132006)
24. Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, et al. National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 years experience. J Antimicrob Chemother. 2013;68:954-9.
25. Matsushima A, Tasaki O, Tomono K, Ogura H, Kuwagata Y, Sugimoto H, et al. Pre-emptive contact precautions for intubated patients reduced healthcare-associated meticillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit. J Hosp Infect. 2011;78:97-101.
26. Yamakawa K, Tasaki O, Fukuyama M, Kitayama J, Matsuda H, Nakamori Y, et al. Assessment of risk factors related to health-care-associated methicillin-resistant Staphylococcus aureus infection at patient admission to an intensive care unit in Japan. BMC Infect Dis. 2011;11:303.
27. Donnio PY, Louvet L, Preney L, Nicolas D, Avril JL, Desbordes L. Nine-year surveillance of methicillin-resistant Staphylococcus aureus in a hospital suggests instability of mecA DNA region in an epidemic strain. J Clin Microbiol. 2002;40:1048-52. (Pubitemid 34208665)
28. Donnio PY, Preney L, Gautier-Lerestif AL, Avril JL, Lafforgue N. Changes in staphylococcal cassette chromosome type and antibiotic resistance profile in methicillin-resistant Staphylococcus aureus isolates from a French hospital over an 11 years period. J Antimicrob Chemother. 2004;53:808-13. (Pubitemid 38660283)
29. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1999;43:1412-6. (Pubitemid 29259335)
30. Climo MW, Sepkowitz KA, Zuccotti G, Fraser VJ, Warren DK, Perl TM, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med. 2009;37:1858-65.
31. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol. 2007;28:1155-61. (Pubitemid 47580458)
32. Wendt C, Schinke S, Wurttemberger M, Oberdorfer K, Bock-Hensley O, von Baum H. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol. 2007;28:1036-43. (Pubitemid 47345262)
33. Kaufhold A, Behrendt W, Krauss T, van Saene H. Selective decontamination of the digestive tract and methicillin-resistant Staphylococcus aureus. Lancet. 1992;339:1411-2.
34. Nau R, Ruchel R, Mergerian H, Wegener U, Winkelmann T, Prange HW. Emergence of antibiotic-resistant bacteria during selective decontamination of the digestive tract. J Antimicrob Chemother. 1990;25:881-3. (Pubitemid 20183054)
35. Saunders GL, Hammond JM, Potgieter PD, Plumb HA, Forder AA. Microbiological surveillance during selective decontamination of the digestive tract (SDD). J Antimicrob Chemother. 1994;34:529-44. (Pubitemid 24344525)
36. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, Sarubbi FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol. 2000;21:459-64. (Pubitemid 30620214)
37. Perez-Roth E, Lopez-Aguilar C, Alcoba-Florez J, Mendez-Alvarez S. High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages. Antimicrob Agents Chemother. 2006;50:3207-11. (Pubitemid 44396442)
38. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med. 1996;156:1109-12. (Pubitemid 26158068)
39. Hudson IR. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect. 1994;27:81-98. (Pubitemid 24200510)
40. Fawley WN, Parnell P, Hall J, Wilcox MH. Surveillance for mupirocin resistance following introduction of routine perioperative prophylaxis with nasal mupirocin. J Hosp Infect. 2006;62:327-32. (Pubitemid 43192324)
41. Vivoni AM, Santos KR, de-Oliveira MP, Giambiagi-deMarval M, Ferreira AL, Riley LW, et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol. 2005;26:662-7. (Pubitemid 41073410)
42. Lee AS, Macedo-Vinas M, Francois P, Renzi G, Schrenzel J, Vernaz N, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis. 2011;52:1422-30.